Literature DB >> 4038510

High-dose cisplatin with sodium thiosulfate protection.

C E Pfeifle, S B Howell, R D Felthouse, T B Woliver, P A Andrews, M Markman, M P Murphy.   

Abstract

Nephrotoxicity frequently limits the dose of cisplatin to less than 120 mg/m2 per injection. Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin. Cisplatin was administered over the last two hours of the thiosulfate infusion. Using this technique, it was possible to escalate the cisplatin dose to 225 mg/m2 before dose-limiting toxicities were encountered. Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. The total drug exposure for the plasma was approximately twofold at the higher cisplatin dose. This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4038510     DOI: 10.1200/JCO.1985.3.2.237

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  38 in total

1.  Selecting dose-intense drug combinations: metastatic breast cancer.

Authors:  E L Korn; R Simon
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

Review 2.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

Review 4.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 5.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

6.  Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.

Authors:  R B Vance; J Pittisapu; J P Kapp
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

7.  Unusual cervical spinal cord toxicity associated with intra-arterial carboplatin, intra-arterial or intravenous etoposide phosphate, and intravenous cyclophosphamide in conjunction with osmotic blood brain-barrier disruption in the vertebral artery.

Authors:  D Fortin; L D McAllister; G Nesbit; N D Doolittle; M Miner; E J Hanson; E A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  1999 Nov-Dec       Impact factor: 3.825

8.  Sodium thiosulfate fails to increase the therapeutic index of intravenously administered cis-diamminedichloroplatinum (II) in mice bearing murine and human tumors.

Authors:  S Aamdal; O Fodstad; A Pihl
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Application of a neuroprotective ACTH(4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs.

Authors:  F P Hamers; S F Klis; W H Gispen; G F Smoorenburg
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

10.  Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine.

Authors:  V B Grossie; D M Ota; J A Ajani; K Nishioka
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.